| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 293 | 886 | ||
| Accounts receivable, net | 2,619 | 2,071 | ||
| Inventories, net | 1,213 | 1,313 | ||
| Prepaid expenses and other current assets | 661 | 745 | ||
| Total current assets | 4,786 | 5,015 | ||
| Property and equipment, gross | 509 | - | ||
| Less accumulated depreciation | 381 | - | ||
| Property and equipment, net | 128 | 143 | ||
| Right of use assets | 799 | 830 | ||
| Investment in convertible bond | 14,876 | 17,188 | ||
| Other assets | 167 | 168 | ||
| Total assets | 20,756 | 23,344 | ||
| Accounts payable and accrued expenses | 21,759 | 19,373 | ||
| Operating lease liabilities, current portion | 348 | 348 | ||
| Other current liabilities | 14,475 | 14,139 | ||
| Warrant derivative liabilities | 11 | 13 | ||
| Notes payable, current portion, net of discount-Nonrelated Party | 7,640 | 8,267 | ||
| Notes payable, current portion, net of discount-Related Party | 3,132 | 3,132 | ||
| Convertible notes payable, net of discount | 16,804 | 16,804 | ||
| Total current liabilities | 64,169 | 62,076 | ||
| Operating lease liabilities, less current portion | 1,498 | 1,584 | ||
| Other long-term liabilities | 12,313 | 13,128 | ||
| Notes payable, less current portion, net of discount-Related Party | 2,264 | 2,257 | ||
| Total liabilities | 80,244 | 79,045 | ||
| Common stock, par value 0.001 per share, 250,000,000 shares authorized, 63,865,571 shares issued and outstanding at september 30, 2025 and december 31, 2024 | 64 | 64 | ||
| Additional paid-in capital | 225,914 | 225,905 | ||
| Net loan receivable from ej holdings | 16,869 | 16,869 | ||
| Accumulated other comprehensive loss | -481 | 1,239 | ||
| Accumulated deficit | -268,116 | -266,040 | ||
| Total stockholders deficit | -59,488 | -55,701 | ||
| Total liabilities and stockholders' deficit | 20,756 | 23,344 | ||
Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. (EMMA)